论文部分内容阅读
目的评价阿托伐他汀治疗肺源性心脏病的临床疗效,并评价其部分作用机制。方法选择2007年1月至2011年3月收治的60例肺源性心脏病患者,随机分为治疗组和对照组,两组均给予常规治疗方案,治疗组在对照组治疗方案基础上加用阿托伐他汀治疗6周,观察呼吸困难情况,检测一氧化氮(NO)、内皮素(ET-1)、脑尿钠肽(BNP)、肺动脉压、Tei指数。结果治疗组治疗后NO较疗前和对照组治疗后均有明显升高(P<0.05),ET-1、BNP、Tei指数、肺动脉压比同组治疗前及常规组治疗月后均有明显下降(P<0.05),呼吸困难症状改善治疗组有效率(63.6%)高于对照组(32.0%),两组间差异有统计学意义(P<0.05)。结论阿托伐他汀能够改善肺心病患者呼吸困难症状,其临床疗效机制与升高
Objective To evaluate the clinical efficacy of atorvastatin in the treatment of pulmonary heart disease and to evaluate its partial mechanism of action. Methods Sixty patients with pulmonary heart disease admitted from January 2007 to March 2011 were randomly divided into treatment group and control group. Both groups were given conventional treatment. The treatment group was added on the basis of the control group Atorvastatin treatment for 6 weeks, observation of dyspnea, detection of nitric oxide (NO), endothelin (ET-1), brain natriuretic peptide (BNP), pulmonary artery pressure, Tei index. Results After treatment, NO in treatment group was significantly higher than that before treatment and in control group after treatment (P <0.05). ET-1, BNP, Tei index and pulmonary arterial pressure were significantly higher than before treatment and after treatment (P <0.05). The improvement rate of dyspnea was higher in the treatment group (63.6%) than in the control group (32.0%), with significant difference between the two groups (P <0.05). Conclusions Atorvastatin can improve the symptoms of dyspnea in patients with pulmonary heart disease, and its clinical therapeutic mechanism and increase